RELATION BETWEEN BIORESORBABLE SCAFFOLD SIZING USING QCA-DMAX AND CLINICAL OUTCOMES AT 2 YEARS IN 1192 PATIENTS FROM THREE STUDY COHORTS (ABSORB COHORT B, ABSORB EXTEND AND ABSORB II)

Implantation of an oversized Absorb scaffold in a relatively small vessel associated with medium-term major adverse cardiac events (MACE). We sought to investigate the long-term MACE ratebased on the appropriateness of device sizing as assessed by Quantitative Coronary Angiography- maximum lumen